AI document generation for biopharma regulatory submissions
Artos AI builds software that helps biopharma clinical and medical writing teams produce regulatory submission documents faster. Its stack pairs OpenAI and Anthropic models with RAG plus Langfuse and LangSmith for LLM observability, a sign that evaluating AI-generated output is a core engineering concern. Hiring is accelerating across engineering, product and sales, with job posts pointing to an early-stage push to formalize sales and engineering processes.
Artos AI is a privately held company headquartered in San Francisco, CA, with 51–200 employees. It develops AI and software tools that convert clinical and R&D data into regulatory documentation for life sciences organizations. Its buyers are clinical development and medical writing teams at biopharma companies working through document-heavy submission workflows. The product runs on a Python and TypeScript stack spanning AWS, Azure and GCP, with deployments into customer enterprise environments.
Artos AI uses Python, FastAPI, Django, React, TypeScript and GraphQL, runs on AWS, Azure and GCP with Docker, Kubernetes, Terraform and Pulumi, and builds on OpenAI, Anthropic, RAG, Langfuse and LangSmith.
Yes. Hiring is accelerating in the United States, led by mid- and senior-level engineering roles, alongside product and sales positions focused on building a sales playbook.
Artos AI is building regulatory and R&D documentation systems, AI-native product experiences, evaluation of AI-generated output, and implementations inside customer enterprise environments.
Other companies in the same industry, closest in size
Artos AI's technology stack, projects, and hiring signals are inferred from public hiring and company data — career pages, public listings, and company web presence — then clustered and de-duplicated. Figures are estimates that refresh over time. Read our full methodology →
This is not an official vendor or customer list. It is a technology-adoption signal inferred from public data, intended for B2B research.